Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01362660 · ClinicalTrials.gov registry record
A Study to Evaluate Infants With Potential Exposure to Tanezumab Before Birth
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 7
- Enrollment target
NCT01362660 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 7 participants.
The verdict
NCT01362660 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 7 participants
- Enrollment target
Study Summary
This study will examine post-natal neurologic and cognitive development of infants who may have been exposed to tanezumab or comparator in-utero during the tanezumab clinical program (whether the exposure is through maternal or paternal participation in a tanezumab clinical study).
Interventions
- OTHER Unintentional exposure in utero
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01362660
The ClinicalTrials.gov registry entry for NCT01362660 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Unintentional exposure in utero is the first listed.
NCT01362660 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01362660 about?
NCT01362660 is a clinical study titled "A Study to Evaluate Infants With Potential Exposure to Tanezumab Before Birth". This study will examine post-natal neurologic and cognitive development of infants who may have been exposed to tanezumab or comparator in-utero during the tanezumab clinical program (whether the exposure is through maternal or paternal participation in a tanezumab clinical study).
What is the current status of trial NCT01362660?
This trial is currently completed. The enrollment target is 7 participants. The study started on 2011-06. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01362660?
The interventions under investigation include: Unintentional exposure in utero (OTHER).
Who is sponsoring clinical trial NCT01362660?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.